GlobeNewsWire
03 Nov 2025, 12:00 UTC · 50w ago
Verdict
Headline takes no side. We score AVTX +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 90% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
3 claims · scored −1 bearish … +1 bullish
Avalo Therapeutics achieved positive topline results in its Phase 2 LOTUS trial of abdakibart for moderate to severe hidradenitis suppurativa (HS).
More positive than 99% of claims this week
The company plans to advance abdakibart into a registrational Phase 3 program.
Continue reading
5 related stories
More positive than 93% of claims this week
Avalo Therapeutics management will participate in four investor conferences between November 10 and December 2, 2025.
More positive than 43% of claims this week
Which stocks this story touches
More positive than 90% of ticker scores this week
The company is participating in multiple investor conferences and reported positive topline results in a Phase 2 clinical trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
11h ago
−61.6%
Price is moving against the score
$6.93 vs $18.03 close before publication (Oct 31) · not market-adjusted
AVTX chart →
